Explore By Subject Area   

Supporting More Participation in Clinical Trials Remotely While Demonstrating ROI: Mobile in Clinical Trials 2024 Recap

This year’s event focused on supporting more patients and sites to participate in clinical trials remotely, while demonstrating ROI.

October 23, 2024
Supporting More Participation in Clinical Trials Remotely While Demonstrating ROI: Mobile in Clinical Trials 2024 Recap

It is our pleasure to share highlights from the 2024 Mobile in Clinical Trials conference, September 16, 2024, Loews Philadelphia Hotel, in Philadelphia, PA.

Click this text to access the full recap


The day opened with two panels providing the Mobile in Clinical Trials audience direct feedback from patients and sites. A patient-led panel shared their preferences and needs for digital technologies in clinical trials, followed by a panel of site representatives who discussed the adoption hurdles they faced in using mobile technologies to enhance clinical trial recruitment and retention.

Novo Nordisk, Abeona Therapeutics, Alcanza, Hawthorne Health and Tufts CSDD discussed the role of mobile health solutions in addressing the evolving landscape of healthcare economics.

In an interactive session, Mobile in Clinical Trials attendees had the chance to brainstorm how they would work through investment challenges, globalization and site readiness and endpoint validation shortage.

Moderna, RWS, Kayentis, Chiesi Farmaceutici, and Merck each demonstrated the impact of mobile technologies in patient engagement, patient-centric digital trial advancements, linguistic design & accessibility. AstraZeneca, Takeda, Clemson Rural Health and Pfizer each demonstrated how mobile technologies were advancing diversity and inclusion, DHT validation, and how they were scaling mobile and digital tech.

There were discussions on the role of AI in mobile technologies and in accelerating participant recruitment/engagement, and using wearable devices to adopt new novel endpoints and digital biomarkers.

Panel discussions tackling some of the industry’s biggest issues included: demonstrating the value and ROI of digital technologies in trials, and globalizing DHT implementation.

The meeting ended with FDA’s Dr Leonard Sacks, Acting Deputy Director, the Office of Medical Policy at the Center for Drug Evaluation and Research, presenting the latest regulatory updates on decentralization and digital health technologies, bringing new light to how the FDA was thinking about mobile and digital technologies.

A big thank you to everyone who participated in this year’s event.

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.